We have studied the role of different conditioning regimens for engraftment of genetically marked hematopoietic repopulating cells in dogs. Peripheral blood (PB) and/or marrow cells collected after treatment with recombinant canine stem cell factor (rcSCF) or cyclophosphamide were transduced in a vector-containing long-term culture system. Three different vector-producing cell lines with similar viral titers were used. In two of them, the neo-containing LN vector was packaged either in the PA317 cell line with an amphotropic murine retrovirus envelope or the PG13 cell line with the gibbon ape leukemia virus (GALV) envelope. The MFG/GC vector produced in PA317 cells contained the human glucocerebrosidase gene. Nineteen dogs received either no conditioning (group A, n = 5). irradiation to both humeri with 1,000 cGy (group B, n = 51, a sublethal dose of cyclophosphamide 40 mg/kg (group C, n = 4). a sublethal dose of 200 or 300 cGy total body irradiation (TB11 (group D, n = 3). or an otherwise lethal dose of 920 cGy TB1 (group E, n = 3) before intravenous (groups A, C, D, E) or intramedullary (group B) infusion of the transduced autologous hematopoietic cells. Transduction efficiency of hematopoietic cells at the time of infusion into the animals was similar among the HETHER ENGRAFTMENT of hematopoietic stem cells (HSC) requires conditioning of the host remains controversial. Early studies in mice showed 100% long-term engraftment of chromosomally marked donor marrow in recipient mice given lethal total body irradiation (TBI).' However, several investigators have since studied transplantation of marrow cells into normal unirradiated syngeneic mice. These efforts were used to study competitive repopulation and to explore potential applications for gene therapy or the induction of donor-specific transplantation tolerance. 24 The first of these studies showed that transfusing normal donor cells into unirradiated recipients gave a maximum of 2% donor cell engraftment.5.6 Based on these results, it was hypothesized that "open" marrow spaces or ''niches" are needed for engraftment of hematopoietic stem cell^.^" This hypothesis was subsequently challenged by a number of investigator^.^.'.^ By increasing the number of donor cells 10-fold, improved engraftment of donor marrow was rep0rted.4.'~ These findings suggested that competitive repopulation occurred in which donor HSC compete equally with host HSC for marrow spaces without the requirement of pretransplant conditioning!
We have previously shown long-term engraftment of transduced canine HSC in recipients conditioned with an otherwise lethal dose of 920 cGy TBI."s'2 However, this was associated with considerable toxicity that would not be acceptable for clinical application in most gene therapy trials." The current study was undertaken to determine whether engraftment of transduced hematopoietic stem cells could be achieved using either no conditioning or conditioning by less toxic regimens. Results show that myelosuppressive, but not myeloablative conditioning, was needed for sustained different conditioning groups. Dogs were observed for at least 6 months. PB granulocytes were obtained at least every 3 weeks after transplant and analyzed by polymerase chain reaction for the presence of the transduced genes. The percentages of positive results in dogs more than 4 weeks after transplantation were 09'0 without Conditioning, 5% with local irradiation, 18% with sublethal cyclophosphamide, 33% with sublethal TBI, and 17% with otherwise lethal TBI. Analyzing the influence of conditioning regimens by a generalized estimating equation (GEE) technique, which considered the use of different retrovirus vectors and the number of mononuclear cells infused as potential confounding variables, we found that engraftment of genetically marked repopulating cells was significantly improved (P < .001) in dogs receiving systemic conditioning with either otherwise lethal TBI, sublethal TBI, or sublethal cyclophosphamide compared to dogs with local irradiation only or no conditioning. Within the limitation of the experimental design, these data suggest that myeloablative or myelosuppressive conditioning improves engraftment of genetically marked hematopoietic repopulating cells. engraftment of the moderate number of genetically marked stem cells currently available in the autologous bone marrow transplantation (ABMT) setting.
MATERIALS AND METHODS

Animals.
The 19 beagle dogs used in this study were either raised in a facility at the Fred Hutchinson Cancer Research Center (FHCRC), approved by the American Association for Accreditation of Laboratory Animal Care or obtained from private USDA-licensed kennels. Animals were kept in holding areas at 70°F ? 2°F with 50% ? 10% relative humidity using at least 15 air changes per hour of 100% conditioned fresh air. Dogs were on a 12-hour lighddark full-spectrum lighting cycle with no twilight. They were dewormed, vaccinated for rabies, distemper, leptospirosis, hepatitis, and parvovirus. Studies were performed according to the "Guide for Laboratory Animal Facilities and Care" prepared by the National Academy of Sciences, National Research Council. The protocols used in this study were approved by the Institutional Animal Care and Use Committee of the FHCRC.
Cell collection and transduction method. Dogs were divided into five groups based on their conditioning regimens. Group A, no conditioning (n = 5); group B, 1,000 cGy local irradiation to both humeri with a linear accelerator at a rate of 380 cGy/min (n = 4); group C, cyclophosphamide 40 mgikg intravenously (IV) (n = 4); group D, 200 cGy (n = 2), or 300 cGy (n = 1) TBI; group E, 920 cGy TB1 (n = 3). Dogs in group D received a single dose of cyclophosphamide, 30 mgkg IV, 7 days before the marrow harvest to induce stem cell cycling. Transduction methods of canine hematopoietic cells in long-term marrow culture (LTMC) have been described." Transduction conditions varied slightly in dogs receiving different conditioning regimens without significantly altering transduction efficiency (Table 1) .
Peripheral blood stem cells (PBSC) were harvested by leukapheresis on two consecutive days (days -7 and -6) after mobilization with recombinant canine stem cell factor (rcSCF), 100 & k g IV twice a day for 7 days (dogs in groups A, B, C, and E). After buffy coat separation, PBSC were cultured in LTMC at 2 to 4 X 10' mononuclear cells (MNC)/mL on an autologous marrow stroma layer established 2 to 3 weeks before. In groups A, B, and C, peripheral blood hematopoietic cells (PBSC) were fed daily for 5 or 6 days with vector-containing supernatant in an LTMC system (LTMC). After the second leukapheresis, marrow was obtained under general anesthesia from both humeri and femora. Buffy coat separated BM cells were cocultivated on irradiated (25 Gy) vector-producing cells in 225-cm2 canted-neck flasks (Coming, Coming, NY) at l to 2 X IOR mononuclear cells per flask in a humidified 7% COL incubator for 24 hours in groups A, B, C, and D. (This step was omitted in dogs in group E.) A mixture of growth factors (recombinant human interleukin-l [rhIL-l], rhIL-3, rhIL-6, and rcSCF, at a final concentration of 50 ng/mL each) and Polybrene (4 pg/mL, Sigma, St Louis, MO) were added on day l and replaced with every supernatant exchange. After cocultivation, adherent and nonadherent cells were harvested and incubated in LTMC, containing 20% pretested horse serum (HS; GIBCO, Grand Island, NY), RPM1 1640 (M.A. Bioproducts, Walkersville, MD), 1% L-glutamine, I % nonessential amino acids, 1% penicillidstreptomycin and hydrocortisone at IO" moll L. LTMC supernatants were demidepleted daily and replaced with fresh cell-free vector-containing medium. PBSC were kept for 5 to 6 days and marrow cells for 4 to 7 days in LTMC. Both adherent and nonadherent cells were harvested, washed twice with phosphatebuffered saline (PBS), filtered, and injected either locally into the humeri of the dogs conditioned with local irradiation, or, in all other dogs, systemically into the external jugular vein. When neocontaining vectors were used, transduction efficiency after LTMC was assessed by G418-resistant colony-foming unit granulocytemacrophage (Cm-GM) colonies as described previously."
Vector packaging cell lines. Three different vector-producing cell lines with similar vector titers were used. Two cell lines, PA3171 LN and PG13/LN, produce vectors carrying the neomycin resistance (neo) gene and have been de~cribed.'~.'~ The other packaging cell line (PA317MFG-GC) produces MFG-GC vector carrying the human glucocerebrosidase (GC) gene. Virus titers were in the range of lo6 to 10' infectious units/mL.
Conditioning regimens and posttransplant care. Before the infusion of the genetically marked autologous hematopoietic cells, dogs received the above-described conditioning regimens. TB1 was ad- ministered as a single dose at a rate of 7 cGy/min from two opposing '"CO sources as described.I6 Posttransplant care included parenteral fluids, systemic antibiotics, and whole blood transfusions that were irradiated with 2,000 cGy cesium radiation before transfusion to inactivate hematopoietic stem cells and immunocompetent cells. In addition, dogs administered TB1 or cyclophosphamide received oral nonabsorbable antibiotics (polymyxin B and neomycin sulfate) three times daily starting on day-5 (day 0 being the day of TB1 and transplantation) until the absolute neutrophil count (ANC) reached 500/mm3 postgrafting. Hematocrits, reticulocytes, leukocytes, platelets, and differential counts were obtained before and daily after day 0 until full hematologic recovery. Dogs that did not show any transduced granulocytes after 6 months were killed, otherwise they were followed for up to 13 months posttransplant. Polymerase chain reaction (PCRJ. PCR was used to show the presence of the neo and the human glucocerebrosidase cDNA in PB granulocytes and lymphocytes obtained at least every 3 weeks for For personal use only. on April 14, 2017. by guest www.bloodjournal.org From For the amplification of the neo gene, the following oligonucleotide primers were used: sense primer neo 350 5' AAG AGA CAG GAT GAA GGA TCG 3', antisense primer neo 1150 5' CAG AAG AAC TCG TCA AGA 3'. sense primer neo 450 5' ACA AAC AGA CAA TCG GCT GCT 3', and antisense primer neo 1027 5' GCC AAC GCT ATG TCC TGA TA 3'. Two micrograms of genomic DNA was amplified by using primers neo 350 and neo 1150 and 2.5 U of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT). Conditions included initial denaturation at 94°C (4 minutes), followed by 30 cycles of 55°C annealing (1 minute), 72°C extension (3 minutes), and 94°C denaturation (1 minute). Reaction products were electrophoresed on 1.5% agarose gels and transferred onto zeta-probe blotting membranes. Hybridization was performed overnight at 42°C using a 32P-labeled 577-bp internal fragment amplified with primers neu 450 and ne0 1027 as described."
To ensure equal amount and quality of DNA, all samples were For amplification of the human GC gene we used the PCR conditions described above with the following oligonucleotide primers: sense primer GC1 5' ACG GCA TCG CAG C'IT GGA TA 3'; antisense primer GC2 5' AGT AGC AAA TIT TGG GCA GG 3'. Hybridization was performed in 50% formamide overnight at 42°C using a 32P-labeled internal fragment." Defection of helper virus in blood. Helper virus in blood or being produced by cells in the blood of dogs was assayed by S+L-assay.14 Briefly, 20 pL fresh blood without anticoagulants was added to 8 mL culture medium (Dulbecco's modified Eagle's medium [DMEM] with 10% FBS) plus 4 ,ug/mL Polybrene (Sigma) and 4-mL samples were added to duplicate 6-cm diameter dishes containing CCC-81 cells seeded the day before at lo4 cells per dish. As a positive control, some dishes received dilutions of the amphotropic serum was prepared from blood samples and duplicate 0.5 mL serum samples were assayed for helper virus in S'L-assay. All dogs tested were negative for helper virus by using either assay.
Srarisricd methods. The analysis was designed to determine whether treating dogs with myelosuppressive conditioning regimens increased the probability of detecting transduced stem cells over that observed in dogs transplanted without myelosuppression. The three groups receiving myelosuppression, groups C, D, and E, were aggregated and statistically tested against dogs not receiving myelosuppressive conditioning (groups A and B combined). To control for possible effects of other variables on the transduction and transplant procedure, the statistical model for probability of detection included factors for type of retrovirus vector, number of MNC infused, and conditioning regimens. The data consisted of multiple observations on individual dogs, so estimation of model parameters and testing for differences between groups required a method that accounted for correlation between observations on the same dog. We used the generalized estimating equation (GEE) technique with an identity link function and an independence working correlation matrix for our analysis. Only data from the first 6 months were included in the analysis. Hypothesis testing procedures for GEE are based on results from large samples. To evaluate that these were applicable in the current setting with a relatively small number of dogs, we performed Monte Carlo simulations under the null hypothesis of no treatment effect. Results indicated that the P values produced by GEE were slightly smaller than expected; however, the magnitude of the bias was not great enough to affect conclusions on any of the comparisons considered."
RESULTS
Nineteen dogs were transplanted according to transduction protocols described above. On day 0, dogs received a median of 0.8 X IO8 MNCkg (range 0.02 X 10' to 2.1 X 10') that had been harvested after transduction in LTMC (Table 1) . In dogs that received neo-transduced HSC, the transduction rate after LTMC ranged from 4% to 12% as determined by G41 8-resistant CFU-GM colonies. No obvious differences in transduction efficiency were seen among different groups. All dogs receiving conditioning had complete hematopoietic reconstitution and survived for at least 6 months (range 6 to 13 months) ( Table l ) . Myelotoxicity of the different conditioning treatments was evaluated by monitoring granulocyte and platelet counts posttransplant. Figures 1 and 2 show granulocyte and platelet counts before and after the transplants. Dogs receiving 920 cGy TB1 (group E) had a more prolonged granulocyte nadir than dogs treated with cyclophosphamide (group C); mean time of neutropenia with an ANC of less than 500/pL was 9 days and 1 day, respectively. Dogs receiving low-dose TB1 (200 cGy) had a slower decline in granulocyte counts and the ANC never decreased below I,OOO/pL (Fig IA) . Decrease in platelet counts and time of thrombocytopenia was similar in dogs given low-dose TB1 or otherwise lethal TBI. Dogs treated with cyclophosphamide had a rapid recovery of platelet counts (Fig IB) . Granu- Table  1 . All dogs tested were negative as determined by vector rescue assay.
For which may persist for years after transplant, and therefore may represent cells already transduced at the time of transplant.'"*" There was no obvious difference in transduction efficiency before infusion of the transduced cells into the recipients among the different conditioning groups, suggesting that the differences in engraftment of transduced HSC were most likely caused by the different conditioning regimens used. We also controlled for possible effects of other variables on the transduction and transplant procedure by including factors for retrovirus vector and MNC number infused in our statistical model.
Our data are in accordance with observations made by Tomita et al: who showed that myelosuppressive conditioning is required to achieve engraftment of murine hematopoietic stem cells when a moderate dose of marrow cells is transplanted. Recipient B6 (H-2h, Ly-5.2) mice received 0, 50, 150, or 300 cGy T B 1 and 1.5 x lo7 T-cell-depleted marrow cells from congeneic Ly-5.1 donors. Using antiLy-5.1 and anti-Ly-5.2 monoclonal antibodies and flow cytometry, the origins of lymphoid and myeloid cells that had reconstituted the animals were observed over time. Although chimerism was detectable initially in all groups, multilineage chimerism in 100% of recipient mice for more than 30 weeks required conditioning with 150 to 300 cGy TBI. These data confirmed earlier studies by Takada et a1,6 who compared engraftment of 10 X 10" marrow cells from CBA/H-6m6T6 mice into irradiated and unirradiated CBA/H hosts. Six months after infusion of donor cells, 80% of dividing BM cells were of donor origin in irradiated mice, whereas only 2% donor cells were seen in unirradiated mice. In a different experimental approach, these investigators compared engraftment of donor marrow cells in mice subjected to local irradiation (800 cGy) of the right femurs only. The percentage of donor-derived marrow cells was about 60% in the irradiated femur and about 1% in the unirradiated femur. These data seem to differ from our observations in dogs subjected to local irradiation. However, in our study transduced cells were injected directly into the marrow cavity, which could have adversely influenced their ability to grow perhaps because of clot formation. Intravenous injection of transduced cells may avoid that problem but has not as yet been tested in the dog.
By increasing donor cell number 5-to 10-fold on each of The data in the mouse described above and our own results suggest that some form of myelosuppression is required to reduce the number of competing endogenous HSC and/or to create "space" or "niches" in the BM to allow significant engraftment of a low number of hematopoietic repopulating cell^.^" The numbers of marrow cells used in most of the studies in unirradiated mice were approximately 80 X lox/ kg. The average number of marrow cells harvested from a conventional BM harvest in a human donor is around 40 times less. An alternative approach for transplanting a higher number of marked HSC in clinical gene therapy trials would be the repeated transfusion of transduced peripheral blood derived HSC which might provide gradual competitive repopulation with transduced HSC.
Bienzle et a124 and Carter et alZ5 described long-term engraftment of retrovirally transduced marrow cells in dogs. After transducing autologous cells in a vector-containing LTMC system for 3 weeks, they found comparable rates of engraftment in conditioned dogs and in dogs that did not receive myeloablative treatment. The presence of genetically marked cells and the expression of the neo gene in CFU-GM assays was seen for up to 2 years in unconditioned animals, although in most animals the number of G418-resistant CW-GM decreased to below 1% by 15 months. This result seems to conflict with our studies in which we did not see any transduced granulocytes in dogs transplanted without conditioning. The discrepancy between these results may be explained by the different transduction protocols used. Carter et alZ5 did not use growth factors and incubated BM cells in retrovirus-containing LTMC system for 3 weeks.
Although our findings do not rule out the possibility that a high number of transduced stem cells could engraft competitively in an unconditioned host, we conclude that myelosuppressive conditioning improves engraftment of the low number of marked stem cells currently available in clinical marrow transplantation. Dogs receiving sublethal cyclophosphamide, sublethal TBI, or otherwise lethal TB1 had comparable engraftment of transduced cells, suggesting that complete myeloablation may not be necessary. These findings are important for current gene therapy trials that rely on optimal engraftment of modified cells, because ex vivo transduction efficiency of repopulating cells has remained low.
